Back

Identification of Malignant Peripheral Nerve Sheath Tumor subtypes with distinct genomic identities

Magallon-Lorenz, M.; Fernandez-Rodriguez, J.; Mazuelas, H.; Uriarte-Arrazola, I.; Ortega-Bertran, S.; Creus-Bachiller, E.; Farres-Casas, J.; Mendez, A.; Rodriguez, E.; Sunol, M.; Rovira, C.; Arnau, R.; Silva, T.; Lopez-Gutierrez, J. C.; Castaneda, A.; Granada, I.; Hernandez-Gallego, A.; Tapia, G.; Saigi, M.; Cucurull, M.; Blanco, I.; Valverde, C.; Romagosa, C.; Salvador, H.; Lazaro, C.; Carrio, M.; Serra, E.; Gel, B.

2026-04-02 cancer biology
10.64898/2026.03.31.715523 bioRxiv
Show abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft-tissue sarcomas arising sporadically or in people with neurofibromatosis type 1 (NF1). Their marked heterogeneity challenges diagnosis and has hampered an integrative view of MPNST molecular pathogenesis. Here, a thorough whole-genome and transcriptome analysis of MPNSTs and the re-analysis of a large independent cohort allowed us to identify three molecular subtypes of MPNSTs (G1-G3) with distinct genomic identities and clinicopathological features. Furthermore, it provided a simple and unifying model of MPNST development, defining a distinct progression path for each group. This work uncovers new genomic aspects of MPNSTs, including the identification of recurrent copy-neutral loss of heterozygosity regions, distinct copy-number profiles among G1-G3, and CDKN2A-inactivating translocations in pre-malignant lesions (ANNUBPs). Altogether, these analyses overcome the dominant influence of PRC2 status in MPNST classification and provide a framework for their differential diagnosis and potential precision oncology treatment. SIGNIFICANCEMPNST is a highly heterogeneous soft-tissue sarcoma with difficult clinical management and no effective systemic therapies. This work defines three molecular subtypes of MPNSTs with distinct development paths and histological and clinical characteristics with potential impact on translational studies and subtype-tailored treatments.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 3%
22.2%
2
Cancer Discovery
61 papers in training set
Top 0.1%
12.5%
3
Science Advances
1098 papers in training set
Top 6%
3.5%
4
Advanced Science
249 papers in training set
Top 6%
3.5%
5
Cancer Cell
38 papers in training set
Top 0.5%
3.5%
6
Cancer Research
116 papers in training set
Top 0.9%
3.5%
7
Cell Reports
1338 papers in training set
Top 17%
3.0%
50% of probability mass above
8
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 26%
2.4%
9
Oncogene
76 papers in training set
Top 0.8%
2.1%
10
Developmental Cell
168 papers in training set
Top 7%
2.1%
11
Genome Medicine
154 papers in training set
Top 4%
1.9%
12
Cell Reports Medicine
140 papers in training set
Top 3%
1.9%
13
eLife
5422 papers in training set
Top 40%
1.8%
14
Nature
575 papers in training set
Top 10%
1.8%
15
Molecular Cancer
14 papers in training set
Top 0.3%
1.7%
16
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.7%
17
Cell Genomics
162 papers in training set
Top 3%
1.7%
18
Acta Neuropathologica
51 papers in training set
Top 0.7%
1.5%
19
Nature Genetics
240 papers in training set
Top 5%
1.3%
20
Cell
370 papers in training set
Top 13%
1.3%
21
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.2%
22
Nature Cancer
35 papers in training set
Top 1%
0.9%
23
Communications Biology
886 papers in training set
Top 19%
0.9%
24
Science Translational Medicine
111 papers in training set
Top 5%
0.8%
25
Frontiers in Oncology
95 papers in training set
Top 4%
0.7%
26
PLOS Biology
408 papers in training set
Top 20%
0.7%
27
Clinical Cancer Research
58 papers in training set
Top 2%
0.7%
28
Cancers
200 papers in training set
Top 5%
0.7%
29
Journal of Clinical Investigation
164 papers in training set
Top 7%
0.7%
30
Nucleic Acids Research
1128 papers in training set
Top 18%
0.7%